Showing posts with label Drug Development. Show all posts
Showing posts with label Drug Development. Show all posts
Monday, December 22, 2014

Big Idea 2015: Haute Apothicaire

›
There are medicines & then there is Haute Apothicaire From what’s written on the wall, 2015 could well be the year when goo...
Thursday, January 30, 2014

Is YODA-enabled clinical data-transparency more than smart externalization of clinical data-mining & analysis?

›
The day started with a news item on Xconomy declaring " J&JOpens Data Vault to Yale, in ‘Unprecedented’ Transparency Move" ...
Tuesday, January 21, 2014

Funds-on-Tap is passé & Drip-Funding is the new reality.

›
It’s probably been true for IT/ ITES ( particularly for e-commerce and social media & app-developers ) much longer, but for the drug...
Sunday, November 10, 2013

So what's wrong if your drug-candidate is likely better-off as a dietary-supplement?

›
In a case-study , the Nov '13 issue of HBR showcases the dilemma of a R&D head grappling with the prospect of a failing clinical p...
Tuesday, October 15, 2013

Deal-Flow : Value-addition :: Silicon-rapids : Organic back-waters

›
Reacting to the rather weird scenario wherein some VCs are trashing their own brotherhood, Bruce Booth wonders in his latest article if t...
1 comment:
Saturday, March 2, 2013

What when the boundaries blur between VC & PE?

›
My response on the highly thought provoking blog post "Venture Capital 2.0"  by Drug Baron (David Grainger) - posted on 01/Mar/2...
1 comment:
Wednesday, February 27, 2013

Dialog on Drug Baron's post "The Primacy of Statistics: In defense of the pivotal Phase 3 Clinical Trial"

›
The Primacy of Statistics: In defense of the pivotal Phase 3 Clinical Trial By Drug Baron (David Grainger) http://www.tcpinnovation...
Wednesday, February 20, 2013

Has the rise of an Indian sun in drug discovery horizon turned out a no-show? OR is it a mere eclipse?

›
Looking up on google to put together my next post, I typed out the text “ Drug discovery prospects India” and the top most hit was that of...
2 comments:
Sunday, February 3, 2013

Pfizer Venture Investments (PVI) - a quick analysis of portfolio companies, categories

›
Trying to understand the driving factors behind the trends of life science investments in 2012, I was wondering if VC & CVCs behave dif...
1 comment:
Monday, January 28, 2013

Drug discovery unable to attract big money! - Is innovation, rather the lack of it to blame?

›
Some interesting observations on early-stage funding for healthcare from the 2012 Venture Capital Activity Report published by  CB Insight...
Thursday, January 24, 2013

The clinical attrition of INX-189 post a 2.5 billion acquisition - are investors into life sciences really looking at where the buck is headed?

›
October 2012 Discussion initiated on Global Private Equity & Venture Capital  group on Linkedin http://www.linkedin.com/groupItem?vi...
1 comment:

INX-189 clinical attrition - a call for re-look at single isomer strategy of Gilead?

›
October 2012 Discussion posted Pharmaceutical Discussion Group on LinkedIn http://www.linkedin.com/groups/INX-189-clinical-attrition...